Changes in Total IgE Plasma Concentration Measured at the Third Month during Anti-IgE Treatment Predict Future Exacerbation Rates in Difficult-to-Treat Atopic Asthma: A Pilot Study

References

• Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. Allergy 2007; 62:216–223.
   PubMed Web of Science ®Google Scholar
• De Marco R, Cazzoletti L, Cerveri I, Corsico A, Bugiani M, Accordini S, Carrozzi L, Dallari R, De Togni A, Marinoni A, Pirina P, Janson C; ISAYA Study Group6. Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int Arch Allergy Immunol 2005; 138:225–234.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372:1073–1087.
   PubMed Web of Science ®Google Scholar
• Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2006; (2):CD003559.
   Google Scholar
• Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008; 102:1371–1378.
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254–261.
   PubMed Web of Science ®Google Scholar
• Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164:S12–S17.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709–717.
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583–593.
   PubMed Web of Science ®Google Scholar
• Ayers JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59:701–708.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD; Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632–638.
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayers J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma whoa are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–316.
   PubMed Web of Science ®Google Scholar
• FDA Omalizumab Product Approval Information Sheet, 20 June 2003.
   Google Scholar
• Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the asthma control test. J Allergy Clin Immunol 2009; 124(4):719–723.
   PubMed Web of Science ®Google Scholar
• Ko FW, Leung TF, Hui DS, Chu HY, Wong GW, Wong E, Tung AH, Lai CK. Asthma control test correlates well with the treatment decisions made by asthma specialists. Respirology 2009; 14(4):559–566.
   PubMed Web of Science ®Google Scholar
• Quanjer H, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Official statement of the European Respiratory Society. Eur Respir J 1993; 6(Suppl. 16):5–40.
   PubMed Web of Science ®Google Scholar
• Tognella S, Dal Negro RW. Omalizumab: una risposta terapeutico-gestionale per il controllo dell’asma grave resistente. It J Chest Dis 2007; 61:390–394.
   Google Scholar
• Piccolo D. Statistica. 2nd ed. Bologna, Italy: Il Mulino Publications, 2002.
   Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6(3):217–227.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60(3): 302–8.
   Google Scholar
• Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, Champain K, Fox H, Thirlwell J. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Resp J 2002; 20:1088–1094.
   PubMed Web of Science ®Google Scholar
• Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, Fowler-Taylor A, Liu J, Gupta N. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111:278–284.
   PubMed Web of Science ®Google Scholar
• Chipps B, Kim K, Koreblat P, Deniz, Y, Carroll, A. Effect of omalizumab on health care utilization in patients with moderate-to-severe allergic asthma. Poster presented at the American Academy of Allergic Asthma and Immunology, 7–12 March 2003, Denver, CO.
   Google Scholar
• Israel E, Cohn JR, Meltzer EO, McCarty J, Zheng B, Carroll A. Omalizumab does not induce thrombocytopenia in the treatment of asthma. Poster presented at the American Academy of Allergic Asthma and Immunology, 7–12 March 2003, Denver, CO.
   Google Scholar
• Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007; 62:149–153.
   PubMed Web of Science ®Google Scholar